FHIR © HL7.org  |  FHIRsmith 0.14.2  |  Server Home  |  XIG Home  |  XIG Stats  | 

FHIR IG analytics

Packagede.medizininformatikinitiative.kerndatensatz.onkologie
Resource TypeMedicationStatement
IdMedicationStatement-mii-exa-onko-modification-oxaliplatin-phase1.json
FHIR VersionR4

Resources that use this resource

No resources found


Resources that this resource uses

No resources found


Narrative

Note: links and images are rebased to the (stated) source


English


Generated Narrative: MedicationStatement mii-exa-onko-modification-oxaliplatin-phase1

basedOn: CarePlan: identifier = Tumorkonferenz_FOLFOX_Modification_001; status = active; intent = plan; category = prätherapeutische Tumorkonferenz (Festlegung der Therapiestrategie); created = 2024-03-05

partOf: Procedure Nicht komplexe Chemotherapie

status: Stopped

statusReason: Grade 3 peripheral neuropathy (CTCAE) - cumulative neurotoxicity from oxaliplatin

medication: Oxaliplatin

subject: Martin Beispiel Male, DoB: 1958-11-03

effective: 2024-03-15 --> 2024-06-10

note:

FOLFOX4 - Cycles 1-6 only. Discontinued due to severe peripheral neuropathy. Patient experienced numbness and tingling in hands and feet (grade 3 CTCAE), interfering with daily activities.


German


Generated Narrative: MedicationStatement mii-exa-onko-modification-oxaliplatin-phase1

basedOn: CarePlan: identifier = Tumorkonferenz_FOLFOX_Modification_001; status = active; intent = plan; category = prätherapeutische Tumorkonferenz (Festlegung der Therapiestrategie); created = 2024-03-05

partOf: Procedure Nicht komplexe Chemotherapie

status: Stopped

statusReason: Grade 3 peripheral neuropathy (CTCAE) - cumulative neurotoxicity from oxaliplatin

medication: Oxaliplatin

subject: Martin Beispiel Male, DoB: 1958-11-03

effective: 2024-03-15 --> 2024-06-10

note:

FOLFOX4 - Cycles 1-6 only. Discontinued due to severe peripheral neuropathy. Patient experienced numbness and tingling in hands and feet (grade 3 CTCAE), interfering with daily activities.


Source1

{
  "resourceType": "MedicationStatement",
  "id": "mii-exa-onko-modification-oxaliplatin-phase1",
  "meta": {
    "profile": [
      "https://www.medizininformatik-initiative.de/fhir/ext/modul-onko/StructureDefinition/mii-pr-onko-systemische-therapie-medikation"
    ]
  },
  "text": {
    "status": "generated",
    "div": "<!-- snip (see above) -->"
  },
  "basedOn": [
    {
      "reference": "CarePlan/mii-exa-onko-tumorkonferenz-folfox-modification"
    }
  ],
  "partOf": [
    {
      "reference": "Procedure/mii-exa-onko-folfox-phase1"
    }
  ],
  "status": "stopped",
  "statusReason": [
    {
      "coding": [
        {
          "system": "http://snomed.info/sct",
          "code": "281647001",
          "display": "Adverse reaction (disorder)"
        }
      ],
      "text": "Grade 3 peripheral neuropathy (CTCAE) - cumulative neurotoxicity from oxaliplatin"
    }
  ],
  "medicationCodeableConcept": {
    "coding": [
      {
        "system": "http://fhir.de/CodeSystem/bfarm/atc",
        "code": "L01XA03",
        "display": "Oxaliplatin"
      }
    ],
    "text": "Oxaliplatin"
  },
  "subject": {
    "reference": "Patient/example-modification"
  },
  "effectivePeriod": {
    "start": "2024-03-15",
    "end": "2024-06-10"
  },
  "note": [
    {
      "text": "FOLFOX4 - Cycles 1-6 only. Discontinued due to severe peripheral neuropathy. Patient experienced numbness and tingling in hands and feet (grade 3 CTCAE), interfering with daily activities."
    }
  ]
}